Enable Injections Enter into Development Agreement with Genentech
The companies will work together to produce enFuse, a patient-administered subcutaneous delivery device.
Device manufacturer Enable Injections, Inc. announced it has entered into a development agreement with Genentech for programs using Enable’s enFuse, an investigational wearable infusion device that allows patient-administered subcutaneous delivery of high-volume therapeutics. The collaboration has the potential for multiple molecule development programs incorporating long-term manufacturing and supply arrangements.
According to an Aug. 21, 2019 press release, the device is an on-body drug delivery platform with a drug transfer system compatible with standard syringes or vial container formats. It is designed for subcutaneous administration of large volumes ranging up to 50 mL and has the potential to provide patients and caregivers with an alternative delivery method for subcutaneous administration of parenteral therapies outside of a clinical setting.
“Enable Injections is pleased to partner with Genentech in its focus on delivering patient-focused solutions,” said Michael D. Hooven, Enable Injections founder, president, and CEO, in the press release. “With the enFuse paired to deliver selected subcutaneous therapeutics, it can potentially benefit patients worldwide.”
Source: Enable Injections, Inc.
FDA Approves Novartis Oral Treatment for Adults with C3 Glomerulopathy
March 25th 2025Fabhalta (iptacopan) received a positive opinion for treatment of C3G from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and has been approved twice before by FDA.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
